Chimeric antigen receptor (CAR) T-cells in acute B-cell leukemia T-Zellen mit chimärem Antigenrezeptor (CAR) bei akuter B-Zell-Leukämie
Hudecek M (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Journal
Book Volume: 14
Pages Range: 20-25
Journal Issue: 1-2
DOI: 10.1007/s11654-018-0117-3
Abstract
The clinical approval of gene-engineered CD19-specific (CD: cluster of differentiation) chimeric antigen receptor T-cells (CD19-CAR T-cells) for the treatment of acute lymphoblastic leukemia (ALL) has marked a new era of personalized cancer immunotherapy in Germany. The innovative mode-of-action is that antigen recognition by the CAR triggers the release of cytolytic granules and cytokines that lead to elimination of leukemic cells expressing the CD19 antigen. CAR T‑cells are a ‘living drug’ that can persist for months and potentially years in the patient’s body after a single infusion, thereby conferring leukemia eradication and also protection from relapse. CAR T-cell therapy will be available at specialized centers with experience in immunotherapy and has the potential to profoundly change and improve the treatment of hematologic malignancies.
Involved external institutions
Germany (DE)How to cite
APA:
Hudecek, M. (2019). Chimeric antigen receptor (CAR) T-cells in acute B-cell leukemia T-Zellen mit chimärem Antigenrezeptor (CAR) bei akuter B-Zell-Leukämie. Best Practice Onkologie, 14(1-2), 20-25. https://dx.doi.org/10.1007/s11654-018-0117-3
MLA:
Hudecek, M.. "Chimeric antigen receptor (CAR) T-cells in acute B-cell leukemia T-Zellen mit chimärem Antigenrezeptor (CAR) bei akuter B-Zell-Leukämie." Best Practice Onkologie 14.1-2 (2019): 20-25.
BibTeX: Download